Listing of the Claims:

The listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Currently Amended) A ~~compounds~~ compound of formula I:



I

wherein:

R^1 is selected from:

1) H, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_{3-6} cycloalkyl, and heterocycle, unsubstituted or substituted with one or more substituents independently selected from:
   a) C_{1-6} alkyl,
   b) C_{3-6} cycloalkyl,
   c) aryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R^4,
   d) heteroaryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R^4,
   e) heterocycle, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R^4,
   f) $(F)_pC_{1-3}$ alkyl,
   g) halogen,
   h) OR^4,
   i) $O(CH_2)_s OR^4$,
   j) CO_2R^4,
   k) $(CO)NR^{10}R^{11}$,

l) $O(CO)NR^{10}R^{11}$,
m) $N(R^4)(CO)NR^{10}R^{11}$,
n) $N(R^{10})(CO)R^{11}$,
o) $N(R^{10})(CO)OR^{11}$,
p) $SO_2NR^{10}R^{11}$,
q) $N(R^{10})\ SO_2R^{11}$,
r) $S(O)_mR^{10}$,
s) CN,
t) $NR^{10}R^{11}$,
u) $N(R^{10})(CO)NR^4R^{11}$, and
v) $O(CO)R^4$; and

2) aryl or heteroaryl, unsubstituted or substituted with one or more substituents independently selected from:

a) $C_{1\text{-}6}$ alkyl,
b) $C_{3\text{-}6}$ cycloalkyl,
c) aryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R^4,
d) heteroaryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R^4,
e) heterocycle, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R^4,
f) $(F)_pC_{1\text{-}3}$ alkyl,
g) halogen,
h) OR^4,
i) $O(CH2)_sOR^4$,
j) CO_2R^4,
k) $(CO)NR^{10}R^{11}$,
l) $O(CO)NR^{10}R^{11}$,
m) $N(R^4)(CO)NR^{10}R^{11}$,
n) $N(R^{10})(CO)R^{11}$,
o) $N(R^{10})(CO)OR^{11}$,
p) $SO_2NR^{10}R^{11}$,
q) $N(R^{10})\ SO_2R^{11}$,
r) $S(O)_mR^{10}$,
s) CN,

t) $NR^{10}R^{11}$,

u) $N(R^{10})(CO)NR^4R^{11}$, and

v) $O(CO)R^4$; and

R^2 is independently selected from H and:

1) C_{1-6} alkyl,
2) C_{3-6} cycloalkyl,
3) aryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R^4,
4) heteroaryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R^4,
5) heterocycle, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R^4,
6) $(F)_pC_{1-3}$ alkyl,
7) halogen,
8) OR^4,
9) $O(CH_2)_sOR^4$,
10) CO_2R^4,
11) $(CO)NR^{10}R^{11}$,
12) $O(CO)NR^{10}R^{11}$,
13) $N(R^4)(CO)NR^{10}R^{11}$,
14) $N(R^{10})(CO)R^{11}$,
15) $N(R^{10})(CO)OR^{11}$,
16) $SO_2NR^{10}R^{11}$,
17) $N(R^{10})\ SO_2R^{11}$,
18) $S(O)_mR^{10}$,
19) CN,
20) $NR^{10}R^{11}$,
21) $N(R^{10})(CO)NR^4R^{11}$, and
22) $O(CO)R^4$;

R^7 is selected from:

1) H, C_0-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_{3-6} cycloalkyl and heterocycle, unsubstituted or substituted with one or more substituents independently selected from:
   a) C_{1-6} alkyl,
   b) C_{3-6} cycloalkyl,
   c) aryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R^4,
   d) heteroaryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R^4,
   e) heterocycle, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R^4,
   f) $(F)_pC_{1-3}$ alkyl,
   g) halogen,
   h) OR^4,
   i) $O(CH_2)_sOR^4$,
   j) CO_2R^4,
   k) $(CO)NR^{10}R^{11}$,
   l) $O(CO)NR^{10}R^{11}$,
   m) $N(R^4)(CO)NR^{10}R^{11}$,
   n) $N(R^{10})(CO)R^{11}$,
   o) $N(R^{10})(CO)OR^{11}$,
   p) $SO_2NR^{10}R^{11}$,
   q) $N(R^{10})\ SO_2R^{11}$,
   r) $S(O)_mR^{10}$,
   s) CN,
   t) $NR^{10}R^{11}$,
   u) $N(R^{10})(CO)NR^4R^{11}$,
   v) $O(CO)R^4$; and

2) aryl or heteroaryl, unsubstituted or substituted with one or more substituents independently selected from:
   a) C_{1-6} alkyl,
   b) C_{3-6} cycloalkyl,
   c) aryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R^4,
   d) heteroaryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R^4,

e) heterocycle, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R^4,

f) $(F)_pC_{1-3}$ alkyl,

g) halogen,

h) OR^4,

i) $O(CH_2)_sOR^4$,

j) CO_2R^4,

k) $(CO)NR^{10}R^{11}$,

l) $O(CO)NR^{10}R^{11}$,

m) $N(R^4)(CO)NR^{10}R^{11}$,

n) $N(R^{10})(CO)R^{11}$,

o) $N(R^{10})(CO)OR^{11}$,

p) $SO_2NR^{10}R^{11}$,

q) $N(R^{10})\ SO_2R^{11}$,

r) $S(O)_mR^{10}$,

s) CN,

t) $NR^{10}R^{11}$,

u) $N(R^{10})(CO)NR^4R^{11}$, and

v) $O(CO)R^4$;

R^4 is selected from: H, C_{1-6} alkyl, $(F)_pC_{1-6}$ alkyl, C_{3-6} cycloalkyl, aryl, heteroaryl and benzyl, unsubstituted or substituted with halogen, hydroxy or C_1-C_6 alkoxy;

R^5 is independently selected from H, substituted or unsubstituted C_1-C_6 alkyl, C_{3-6} cycloalkyl, aryl, heteroaryl, OR^4, $N(R^4)_2$, CO_2R^4 and $(F)_pC_{1-6}$ alkyl;

W is O, NR^4 or $C(R^4)_2$;

X is C or S;

Y is O, $(R^4)_2$, NCN, NSO_2CH_3 or $NCONH_2$, or Y is O_2 when X is S;

R^3 is independently selected from H, substituted or unsubstituted C_1-C_3 alkyl, CN and CO_2R^4;

R^6 is independently selected from H and:

a) C_{1-6} alkyl,

b) C_{3-6} cycloalkyl,

c) aryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R^4,

d) heteroaryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R^4,

e) heterocycle, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R^4,

f) $(F)_pC_{1-3}$ alkyl,

g) halogen,

h) OR^4,

i) $O(CH_2)_sOR^4$,

j) CO_2R^4,

k) $(CO)NR^{10}R^{11}$,

l) $O(CO)NR^{10}R^{11}$,

m) $N(R^4)(CO)NR^{10}R^{11}$,

n) $N(R^{10})(CO)R^{11}$,

o) $N(R^{10})(CO)OR^{11}$,

p) $SO_2NR^{10}R^{11}$,

q) $N(R^{10})\ SO_2R^{11}$,

r) $S(O)_mR^{10}$,

s) CN,

t) $NR^{10}R^{11}$,

u) $N(R^{10})(CO)NR^4R^{11}$, and

v) $O(CO)R^4$;

R^{10} and R^{11} are independently selected from: H, C_{1-6} alkyl, $(F)_pC_{1-6}$ alkyl, C_{3-6} cycloalkyl, aryl, heteroaryl and benzyl, unsubstituted or substituted with halogen, hydroxy or C_1-C_6 alkoxy, where R^{10} and R^{11} may be joined together to form a ring selected from: azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl and morpholinyl, which is unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R^4;

G-J is selected from: N, N-$C(R^5)_2$, C=$C(R^5)$, C=N; $C(R^5)$, $C(R^5)$-$C(R^5)_2$, $C(R^5)$-$C(R^5)_2$-$C(R^5)_2$, C=$C(R^5)$-$C(R^5)_2$, $C(R^5)$-C(R^5)=$C(R^5)$, $C(R^5)$-$C(R^5)_2$-N(R^5), C=$C(R^5)$-N(R^5), $C(R^5)$-C(R^5)=N, $C(R^5)$-N(R^5)-$C(R^5)_2$, C=N-$C(R^5)_2$, $C(R^5)$-N=$C(R^5)$, $C(R^5)$-N(R^5)-N(R^5), C=N-N(R^5), N-$C(R^5)_2$-$C(R^5)_2$, N-C(R^5)=$C(R^5)$, N-$C(R^5)_2$-N(R^5), N-C(R^5)=N, N-N(R^5)-$C(R^5)_2$ and N-N=$C(R^5)$;

Q, T, U and V are each independently a carbon atom or a nitrogen atom wherein at least one but no more than three of Q, T, U and V are nitrogen atoms, and wherein when any of Q, T, U, or V is a carbon atom it is unsubstituted or substituted where the substituents are independently selected from R^6;

p is	0 to 2q+1, for a substituent with q carbons;
m is	0, 1 or 2;
n is	0 or 1;
s is	1, 2 or 3;

and pharmaceutically acceptable salts and individual diastereomers thereof.

2. The compound of claim 1 of the formula Ia:



and pharmaceutically acceptable salts and individual diastereomers thereof.

3. The compound of claim 2, wherein R^7 is phenyl, unsubstituted or substituted with one or substituents independently selected from:

a) C_{1-6} alkyl,
b) OH,
c) OR^5,
d) halogen,
e) CO_2R^4,
f) $S(O)_mR^5$,
g) $N(R^4)_2$, and
j) CN,

and pharmaceutically acceptable salts and individual diastereomers thereof.

4. The compound of claim 2, wherein R^7 is heteroaryl, unsubstituted or substituted with one or substituents independently selected from:

a) C_{1-6} alkyl,
b) OH,
c) OR^5,
d) halogen,
e) CO_2R^4,

f) $S(O)_mR^5$,

g) $N(R^4)_2$, and

j) CN,

and pharmaceutically acceptable salts and individual diastereomers thereof.

5. The compound of claim 2, wherein R^7 is selected from H and C_1-C_6 alkyl, C_1-C_6 alkenyl, C_1-C_6 alkynyl, C_3-C_6 cycloalkyl, unsubstituted or substituted with one or substituents independently selected from:

a) C_{1-6} alkyl,

b) C_{1-6} alkoxy,

c) fluorine,

d) HO,

e) OR^5,

f) CO_2R^4,

g) $CON(R^4)_2$,

h) $S(O)_mR^5$, and

i) $N(R^4)_2$; and

and pharmaceutically acceptable salts and individual diastereomers thereof.

6. The compound of claim 2, wherein R^7 is heterocycle, unsubstituted or substituted with one or substituents independently selected from:

a) C_{1-6} alkyl,

b) C_{1-6} alkoxy,

c) fluorine,

d) HO,

e) OR^5,

f) CO_2R^4,

g) $CON(R^4)_2$,

h) $S(O)_mR^5$, and

i) $N(R^4)_2$; and

and pharmaceutically acceptable salts and individual diastereomers thereof.

7. The compound of claim 1 of the formula Ib:



Ib

and pharmaceutically acceptable salts and individual diastereomers thereof.

8. The compound of claim 1 of the formula Ic:



Ic

and pharmaceutically acceptable salts and individual diastereomers thereof.



9. The compound of claim 1 of the formula Id:



Id

and pharmaceutically acceptable salts and individual diastereomers thereof.

10. A compound selected from:

,



,



,















and pharmaceutically acceptable salts and individual diastereomers thereof.

11. A pharmaceutical composition which comprises an inert carrier and the compound of Claim 1.

12. A method for antagonism of CGRP receptor activity in a mammal which comprises the administration of an effective amount of the compound of Claim 1.

13. A method for treating, controlling, ameliorating or reducing the risk of headache, migraine or cluster headache in a mammalian patient in need of such which comprises administering to the patient a therapeutically effective amount of the compound of Claim 1.

14 -57. (Canceled)